OAC
IOVA icon

OMERS Administration Corp’s Iovance Biotherapeutics IOVA Stock Holding History

OMERS Administration Corp’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-69,000
Closed -$230K – 989
2025
Q1 		$230K Buy
+69,000
New +$356K ﹤0.01% 911
2024
Q3 		– Sell
-33,400
Closed -$268K – 984
2024
Q2 		$268K Buy
+33,400
New +$358K ﹤0.01% 825
2020
Q2 		– Sell
-25,300
Closed -$757K – 181
2020
Q1 		$757K Buy
+25,300
New +$671K 0.03% 116

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

OMERS Administration Corp's IOVA Position: Q2 2025 in Review

OMERS Administration Corp sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 69,000 shares — an estimated $230K sold.

OMERS Administration Corp first reported a position in IOVA in Q1 2020 and held it in 3 quarters. The position peaked at $757K in Q1 2020. 254 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • OMERS Administration Corp reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • OMERS Administration Corp sold 69,000 Iovance Biotherapeutics shares in Q2 2025, an estimated $230K.
  • OMERS Administration Corp first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 3 quarters.
  • OMERS Administration Corp's Iovance Biotherapeutics position peaked at $757K in Q1 2020.
  • 254 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on OMERS Administration Corp's 13F filing for Q2 2025, filed 13 Aug 2025.